Abstract
Background: In pre-vaccinated people with multiple sclerosis (MS), certain disease-modifying therapies (DMTs), particularly the anti-CD20 treatments, appear to be associated with an increased risk of COVID-19 infection and indeed with severe infection. It is still not known if such observations extend to vaccinated individuals and there have been considerably fewer studies in aquaporin-4-antibody neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein-antibody associated disease (MOGAD) patients. In this study, we investigated the rates of symptomatic COVID-19 infection in adult patients with MS, AQP4-NMOSD and MOGAD who had received 2 doses of SARS-CoV-2 mRNA vaccine.
Methods: This was a prospective observational study conducted at the 2 main neuroimmunology referral centres in Singapore. Only patients on active follow-up were recruited to ensure robust data collection. Data on demographics, disease history, DMTs and SARS-CoV-2 mRNA vaccinations were recorded, and for those infected with COVID-19, data on COVID-19 infection was collected.
Results: Nineteen (13 MS, 5 AQP4-NMOSD, 1 MOGAD) out of 365 (231 MS, 106 AQP4-NMOSD, 28 MOGAD) patients had COVID-19 infection despite 2 doses of SARS-CoV-2 mRNA vaccine. Amongst the infected patients, 11 patients were on DMTs (3 rituximab, 2 interferons, 1 azathioprine, 1 mycophenolate, 1 prednisolone, 1 cladribine, 1 alemtuzumab, 1 fingolimod), while 8 patients were untreated. The crude infection rate was calculated using time-at-risk analysis, revealing that rituximab had the highest infection rate amongst all the DMTs. A lower crude infection rate was observed in patients who received a third vaccination. The majority of infections were mild and no patients required oxygen supplementation.
Conclusion: Our findings suggest that patients on rituximab are still at risk of COVID-19 infection after 2 vaccinations and the receipt of a third vaccination may help to prevent infection. Future large scale studies will be required to better delineate the infection risk of different DMTs after the second and subsequent vaccinations.
Keywords: COVID-19; MOGAD; Multiple sclerosis; Neuromyelitis optica; Vaccination; Vaccine.
【저자키워드】 COVID-19, vaccination, multiple sclerosis, vaccine., Neuromyelitis Optica, MOGAD, 【초록키워드】 SARS-CoV-2, mRNA vaccination, Severe infection, therapy, mRNA vaccine, prospective observational study, Infection, interferons, COVID-19 infection, symptomatic, Patient, Mild, Follow-up, infection rate, Singapore, infection risk, disease, patients, anti-CD20, Vaccinations, Analysis, dose, Prednisolone, demographics, observation, infected patients, increased risk, help, disorder, Multiple, vaccinated individual, oxygen supplementation, Future, risk of COVID-19, Prevent, robust, highest, recruited, subsequent, investigated, required, conducted, was collected, calculated, majority, were recorded, infected with COVID-19, Neuromyelitis, 【제목키워드】 SARS-CoV-2, mRNA vaccine, COVID-19 infection, dose,